Celgene(NASDAQ: CELG) recently reported that its multiple sclerosis drug, ozanimod, successfully met its endpoints in reducing multiple sclerosis (MS) relapses, and assuming a second trial pans out ...
A new and highly anticipated study byCelgene Corp. (NASDAQ: CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management ...
Which stock wins in a match-up between these two biotechs? Biogen ascended to stardom in the biotech world on the strength of its multiple sclerosis (MS) franchise. This franchise includes blockbuster ...
Celgene has backed out of a $55 million settlement it reached last year in a move legal experts are calling highly unusual, according to STAT. The class-action lawsuit accused Celgene — which was ...
Amgen said Monday that it will buy the psoriasis pill Otezla from Celgene, which is selling the medicine to remove an antitrust obstacle from its planned merger with Bristol-Myers Squibb. The purchase ...
New Jersey-based Celgene will pay $55 million to resolve a class-action suit that accused the drugmaker of blocking generic competition in the cancer market at the expense of patients. The lawsuit ...
REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous ...
(Reuters) - Celgene Corp's treatment for anemia in patients with beta thalassemia, a rare blood disorder, would be priced at $3,441 for a 25-milligram vial of the drug, partner Acceleron Pharma Inc ...
Amgen said Monday that it will buy the psoriasis pill Otezla from Celgene, which is selling the medicine to remove an antitrust obstacle from its planned merger with Bristol-Myers Squibb. The purchase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results